Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies -





Published: April 2015 | Pages: 414 | Format: PDF

This Competitive Intelligence Report about Therapeutic Antibodies 2015: Biosimilars & Biosuperiors provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of April 2015. 

Total sales of recombinant therapeutic monoclonal antibodies originating from companies located in regulated markets reached US$ 82.2 bln (+8.6% vs previous year) in the year 2014.

The report lists specifically for each target the branded products with their 2014 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development.

The report includes a compilation of currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets:

  • VEGF
  • TNF
  • Her2
  • CD20
  • EGF-R
  • B7.1/B7.2 (CD80/CD86)
  • IL-6R
  • Alpha4/beta1/7 integrin
  • IgE
  • RSV
  • RANKL
  • Complement C5
  • IL-12/IL-23
  • CD52

Competitor projects are listed in a tabular format providing information on: 

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

 About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.


 

 


Table of Contents 

1)         2014 Sales of Therapeutic Antibodies
•          Anti-TNF Antibody Sales 2014
•          Cancer Antibody Sales 2014
•          Other Anti-Inflammatory Antibody Sales 2014
•          Ophthalmic Antibody Sales 2014
•          Cardiometabolic & Antiviral Antibody Sales 2014

2)         VEGF Antibodies
Marketed VEGF & VEGF-R Antibodies in Oncology:
•          Avastin Sales & Pipeline
•          Zaltrap Sales & Pipeline
•          Cyramza Sales & Pipeline
Avastin & Zaltrap Biosuperiors:
•          Anti-VEGF & Antibody Combination Pipeline
•          Bispecific Anti-VEGF Antibody Pipeline
Cyramza Biosuperiors:
•          Anti-VEGF-R & Antibody Combination Pipeline
•          Bispecific Anti-VEGF-R Antibody Pipeline
Avastin Biosimilar Pipeline:
Marketed VEGF Antibodies in Ophthalmology:
•          Lucentis Sales & Pipeline
•          Eylea Sales & Pipeline
Biosuperior Lucentis & Eylea Pipeline:
•          Anti-VEGF Pipeline in Ophthalmology
•          Bispecific Anti-VEGF and Antibody Combination Pipeline in Ophthalmology
Lucentis Biosimilar Pipeline

3)         TNF Antibodies
Tab. 1: Approved and marketed indications of anti-TNF antibodies in regulated markets
Tab. 2: Additional indications of branded anti-TNF antibodies under development 
Tab. 3: 2014 Sales of anti-TNF Antibodies
Marketed TNF Antibodies
-           Humira Sales & Pipeline
-           Remicade Sales & Pipeline
-           Enbrel Sales & Pipeline
-           Simponi Sales & Pipeline
-           Cimzia Sales & Pipeline
Biosuperior / Biobetter TNF Antibodies
Biosimilar TNF Antibodies
-           Humira Biosimilar Antibody Pipeline
-           Remicade Biosimilar Antibody Pipeline
-           Enbrel Biosimilar Antibody Pipeline
-           Cimzia Biosimilar Antibody Pipeline

4)         Her2 Antibodies 
Marketed Her2 Antibodies
-           Herceptin Sales & Pipeline
-           Perjeta Sales & Pipeline
-           Kadcyla Sales & Pipeline
Trastuzumab Biosuperiors
-           Engineered Her2 Antibodies
-           Bi- and Multispecific Her2 Antibodies
-           Her2 Antibody-Drug Conjugates
-           Other Her2 Antibodies
Herceptin Biosimilars

5)         CD20 Antibodies 
2014 Sales of CD20 Antibodies
Marketed CD20 Antibodies & Sales
-           Rituxan/MabThera Pipeline & Sales
-           Gazyva/ Gazyvaro Pipeline & Sales
-           Arzerra Pipeline & Sales
-           Zevalin Pipeline & Sales
Biosuperior CD20 Antibodies
Biosimilar CD20 Antibodies
-           Rituxan/MabThera (rituximab) Biosimilars

6)         EGF-R Antibodies 
2014 Sales of EGF-R Antibodies
Marketed EGF-R Antibodies
-           Erbitux Sales & Pipeline
-           Vectibix Sales & Pipeline
-           Nimotuzumab Pipeline
EGF-R Antibody Biosuperiors
-           Engineered EGF-R Antibodies
-           Bi- and Multispecific EGF-R Antibodies
-           EGF-R Antibody-Drug Conjugates
EGF-R Antibody Biosimilars
-           Cetuximab Biosimilars

7)         RANKL Antibodies
Marketed RANKL Antibodies
-           Prolia Sales & Pipeline
-           XGEVA Sales & Pipeline
-           Ranmark/Pralia Pipeline
Biosuperior RANKL Antibodies
Biosimilar RANKL Antibodies

8)         Complement C5 Antibodies
Marketed C5 Antibody Sales & Pipeline
Biosuperior C5 Antibodies
Biosimilar C5 Antibodies

9)         Interleukin-12/-23 Antibodies
Marketed IL-12/-23 Antibody Sales & Pipeline

10)       Alpha4/Beta1/7 Antibodies
Marketed alpha4/beta1/7 Antibody Sales & Pipeline

11)       IgE Antibodies
Marketed IgE Antibody Sales & Pipeline
Biosuperior IgE Antibodies
Biosimilar IgE Antibodies

12)       CD80/86 (B7-1/B7-2) Antibodies
Marketed CD80/86 Antibodies Sales & Pipeline
Biosuperior CD80/86 Antibodies
Biosimilar CD80/86 Antibodies

13)       Interleukin-6 Receptor (IL-6R) Antibodies
Marketed IL-6R Antibody Sales & Pipeline
Biosuperior IL-6R Antibodies
Biosimilar IL-6R Antibodies

14)       Respiratory Syncytial Virus (RSV) Antibodies
Marketed RSV Antibody Sales
Biosuperior RSV Antibodies
Biosimilar RSV Antibodies

15)       CD52 Antibodies
Marketed CD52 Antibody Sales 
Biosuperor CD52 Antibodies
Biosimilar CD52 Antibodies

Corporate Therapeutic Antibody Biosimilar & Biosuperior Pipelines